483
Cdymax (India) Pharma Private LimitedFDA 483 - Cdymax (India) Pharma Private Limited - May 17, 2019
Record Details
An FDA inspection of Acebright (India) Pharma Private Limited, an API drug manufacturer in Jigani, India, revealed a significant deficiency in laboratory controls. The firm failed to establish scientifically sound test procedures, specifically by not using a second working standard solution during chromatographic analysis to confirm the potency, accuracy, and purity of active pharmaceutical ingredients. This indicates a serious lapse in quality control for their drug products.
Open in Dashboard
ID · 6bebb67d-1710-4855-b96c-9c78b3cbb505